NCT00065728View on ClinicalTrials.gov

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

PHASE3TerminatedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Macular Degeneration
Interventions
DRUG

Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL

One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months

Trial Locations (1)

76134

Belgium,France,Germany,Hungary,Italy,Netherlands,Poland,Spain,Sweden,UK, Central Contact Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY